Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LixiLan-L: Insulin Glargine/Lixisenatide FRC vs Insulin Glargine in T2DM
NCT02058160Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2014
- Primary completion
- Jul 2015
- Countries
- 18
01
Overview
A Phase 3 trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Jan 2014; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02058160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058160.